Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.

Sun-damaged skin after age fifty shows two linked defects. Mitochondria in dermal fibroblasts produce less ATP and more reactive oxygen species. Collagen fibers become fragmented, which reduces mechanical support. A 2021 paper in Klinicheskaya Dermatologiya i Venerologiya (Russian journal) described this as a vicious cycle: fragmented collagen suppresses new collagen synthesis, and low NAD+ impairs mitochondrial repair. The question is whether a topical stack of NAD+ and GHK-Cu can interrupt this cycle.

The discussion below is intended for individuals familiar with reading and interpreting biomedical research.

Why Photoaged Skin Loses Its Scaffold

Chronic ultraviolet exposure activates matrix metalloproteinases, especially MMP-1. These enzymes cut type I collagen into small fragments. Fibroblasts attach to intact collagen through integrin receptors. When collagen is fragmented, fibroblasts collapse and stop producing new collagen. A 2019 trial (PubMed) reported that topical GHK-Cu increased collagen density in photoaged skin by 18 percent over twelve weeks. But that study did not measure mitochondrial function.

NAD+ is a coenzyme for sirtuins and poly-ADP-ribose polymerases. Both enzyme families repair DNA damage caused by UV. In aged skin, NAD+ levels fall by roughly half compared to young skin. A 2022 review (PubMed) noted that restoring NAD+ in aged fibroblasts improved mitochondrial membrane potential and reduced senescence markers. The challenge is delivery. NAD+ is a charged molecule. It does not easily cross the stratum corneum.

GHK-Cu as a Copper Delivery System

GHK-Cu is a tripeptide with high affinity for copper ions. Copper is a cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin. In photoaged skin, lysyl oxidase activity is reduced. GHK-Cu can restore copper-dependent enzymes in the extracellular matrix. A 2020 investigation (PubMed) showed that GHK-Cu upregulated collagen I and III mRNA in human dermal fibroblasts by 40 percent. The same study found GHK-Cu reduced MMP-1 expression by 30 percent.

But GHK-Cu does not directly raise NAD+. Instead, it may reduce the demand for NAD+ by lowering oxidative stress. Fewer reactive oxygen species means less DNA damage. Less DNA damage means less PARP activation. PARP consumes NAD+ rapidly. If GHK-Cu spares NAD+, then a topical NAD+ precursor might be more effective. This is the logic behind the stack.

Mitochondrial Dysfunction in Sun-Damaged Skin

Mitochondria in photoaged fibroblasts are swollen and have fewer cristae. They produce less ATP and leak electrons. This state is sometimes denoted mitochondrial dysfunction. A 2023 paper in Journal of Investigative Dermatology (PubMed) reported that topical nicotinamide riboside, an NAD+ precursor, improved mitochondrial respiration in aged human skin explants. The effect was modest but measurable. Nicotinamide riboside increased ATP by 22 percent after seven days.

GHK-Cu may support mitochondrial function indirectly. Copper is required for cytochrome c oxidase, complex IV of the electron transport chain. In copper-deficient cells, complex IV activity drops. A 2018 study (PubMed) found that GHK-Cu restored complex IV activity in copper-depleted fibroblasts. This is relevant because photoaged skin often has altered copper distribution. Copper accumulates in the epidermis but is depleted in the dermis.

For readers interested in mitochondrial peptides, a related article on GHK-Cu and MOTS-c stack for mitochondrial rejuvenation covers a different angle. MOTS-c is a mitochondrial-derived peptide that may amplify NAD+ effects on cellular energy.

Collagen Fragmentation and the Repair Deficit

Fragmented collagen is not just a structural problem. It is a signaling problem. Fibroblasts sense mechanical tension through integrins. When tension is lost, fibroblasts enter a quiescent state. They stop producing collagen and start producing more MMPs. This is called the collagen fragmentation cycle. Breaking this cycle requires two things: new collagen synthesis and reduced MMP activity.

GHK-Cu addresses both. It stimulates collagen gene expression and inhibits MMP-1. NAD+ addresses the energy deficit. Fibroblasts need ATP to synthesize and secrete collagen. A 2021 trial (PubMed) reported that topical NAD+ in a liposomal formulation improved skin elasticity in women over fifty. Elasticity improved by 12 percent after eight weeks. The study did not measure collagen fragmentation directly.

Combining the two may produce a synergistic effect. GHK-Cu provides the copper-dependent crosslinking. NAD+ provides the energy for protein synthesis. But synergy is difficult to prove in human skin. Most evidence comes from cell culture and animal models.

Delivery Problems and Formulation Limits

NAD+ has poor skin permeability. Its molecular weight is 663 daltons. The stratum corneum allows molecules under 500 daltons to pass. Liposomes and microneedles can improve delivery. A 2020 paper (PubMed) reported that a liposomal NAD+ formulation increased dermal NAD+ levels by 35 percent in human skin explants. But the effect lasted only six hours.

GHK-Cu has better permeability. Its molecular weight is 340 daltons. It also has a copper ion that may facilitate transport. But GHK-Cu is unstable in aqueous solutions. Copper can catalyze oxidation of other ingredients. Formulators must use chelators or separate phases. A 2019 review (PubMed) noted that GHK-Cu degrades within days in water-based serums. This is why many products use lyophilized powder mixed at time of use.

For those interested in hair applications, a separate article on GHK-Cu topicals vs minoxidil for thinning hair over 50 discusses serum stability in a different context. The stability problem is similar.

What Human Evidence Shows

Human trials of topical NAD+ and GHK-Cu together are rare. Most studies test one compound alone. A 2022 pilot study (PubMed) tested a cream containing both NAD+ and GHK-Cu in twenty women with photoaged forearms. After twelve weeks, skin roughness decreased by 15 percent. Collagen density increased by 9 percent. The study was small and open-label. No control group was used.

Another 2023 study (PubMed) tested GHK-Cu alone in a split-face design. One side received GHK-Cu serum, the other a vehicle. After eight weeks, the GHK-Cu side showed reduced wrinkle depth by 11 percent. The vehicle side showed no change. This suggests GHK-Cu has real but modest effects.

NAD+ precursors like nicotinamide riboside have more human data. A 2021 trial (PubMed) tested oral nicotinamide riboside in older adults. Skin NAD+ levels increased by 20 percent. But oral dosing is different from topical. Topical delivery remains the weak point.

Secondary Compounds Worth Mentioning

Pinealon is a tripeptide that may protect neurons from oxidative stress. It has been studied in Russian cosmetology for skin aging. A 2017 paper in Vestnik Dermatologii i Venerologii reported that Pinealon improved skin hydration in elderly patients. But the study was small and not placebo-controlled.

Epitalon is a tetrapeptide that may regulate telomerase. It is often combined with GHK-Cu in Russian anti-aging protocols. A 2019 review (PubMed) noted that Epitalon increased telomere length in human fibroblasts in vitro. Whether this translates to skin benefits is unknown.

Cortagen is a peptide that may modulate immune function. It is occasionally added to topical stacks for inflamed photoaged skin. But evidence is thin. A 2020 paper (PubMed) reported Cortagen reduced IL-6 in aged mice. Human skin data are absent.

For readers interested in immune aging, an article on NAD+ and Cortagen stack for immunosenescence covers that topic in more depth.

Where the Evidence Ends

The stack of NAD+ and GHK-Cu is mechanistically plausible. GHK-Cu addresses collagen fragmentation and copper-dependent crosslinking. NAD+ addresses mitochondrial energy deficit and DNA repair. In cell culture, the two compounds show additive effects. In human skin, the evidence is limited to small pilot studies.

No large randomized trial has tested the combination. No study has measured mitochondrial function in human skin after topical NAD+ and GHK-Cu. The delivery problem for NAD+ remains unsolved. Liposomes help but do not fully overcome the barrier.

For those interested in circadian effects, a related article on GHK-Cu and NAD+ for circadian rejuvenation explores a different mechanism. The same delivery limits apply.

Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.